SCHEMBL2988056

SCHEMBL2988056

O=C(Nc1cc(Cl)cc(Cl)c1)C(Cc1nc2ccccc2[nH]c1=O)=NNC(=O)c1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.60
MAPT P10636 6/20 0.48
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 4/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
POLB P06746 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NTRK1 P04629 3/20 0.43
NTRK2 Q16620 3/20 0.43
STK33 Q9BYT3 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
HSD17B10 Q99714 2/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2988054 1.00 PTGES (0.60) PTGESMAPTALDH1A1MEN1KMT2A
SCHEMBL2993011 0.77 PTGES (0.85) PTGESMAPTALDH1A1MEN1KMT2A
SCHEMBL2993013 0.77 PTGES (0.85) PTGESMAPTALDH1A1MEN1KMT2A
SCHEMBL6648776 0.64 NPC1 (0.76) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL11706324 0.63 NPC1 (0.81) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL6842955 0.63 MAPT (0.69) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL11369264 0.62 KDM4E (0.76) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL14642442 0.62 MEN1 (0.79) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL6842954 0.61 KDM4E (0.68) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL29092929 0.60 KDM4E (0.60) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB PTGES 1829/4885MAPT 2862/4885ALDH1A1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.